[{"id":"d2dd03bc-0fae-46dc-868b-5c48fa14ca32","acronym":"","url":"https://clinicaltrials.gov/study/NCT04010877","created_at":"2021-01-18T19:42:18.741Z","updated_at":"2024-07-02T16:36:55.454Z","phase":"Phase 1/2","brief_title":"Multiple CAR-T Cell Therapy Targeting AML","source_id_and_acronym":"NCT04010877","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2019-09-19"}]